Weekly Analysts’ Ratings Changes for Aldeyra Therapeutics (ALDX)

Share on StockTwits

Several analysts have recently updated their ratings and price targets for Aldeyra Therapeutics (NASDAQ: ALDX):

  • 3/14/2019 – Aldeyra Therapeutics was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 3/8/2019 – Aldeyra Therapeutics was given a new $30.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 3/7/2019 – Aldeyra Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Aldeyra Therapeutics, Inc. is a biotechnology company. The company’s products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. “
  • 2/28/2019 – Aldeyra Therapeutics was given a new $30.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 2/19/2019 – Aldeyra Therapeutics was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.
  • 1/29/2019 – Aldeyra Therapeutics was given a new $30.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.

ALDX traded down $0.40 during trading on Friday, reaching $8.32. 11,067 shares of the company’s stock were exchanged, compared to its average volume of 236,996. Aldeyra Therapeutics, Inc has a fifty-two week low of $6.75 and a fifty-two week high of $16.70. The firm has a market capitalization of $246.66 million, a PE ratio of -4.65 and a beta of 0.77.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its earnings results on Friday, March 8th. The biotechnology company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.04. Equities analysts forecast that Aldeyra Therapeutics, Inc will post -1.7 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. FMR LLC grew its holdings in Aldeyra Therapeutics by 59.1% during the 3rd quarter. FMR LLC now owns 2,564,333 shares of the biotechnology company’s stock worth $35,388,000 after acquiring an additional 953,022 shares during the period. 683 Capital Management LLC grew its holdings in Aldeyra Therapeutics by 3.2% during the 4th quarter. 683 Capital Management LLC now owns 1,393,700 shares of the biotechnology company’s stock worth $11,568,000 after acquiring an additional 43,700 shares during the period. BlackRock Inc. grew its holdings in Aldeyra Therapeutics by 63.0% during the 4th quarter. BlackRock Inc. now owns 1,298,715 shares of the biotechnology company’s stock worth $10,779,000 after acquiring an additional 501,927 shares during the period. Sphera Funds Management LTD. grew its holdings in Aldeyra Therapeutics by 7.9% during the 4th quarter. Sphera Funds Management LTD. now owns 1,232,089 shares of the biotechnology company’s stock worth $10,226,000 after acquiring an additional 90,000 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of Aldeyra Therapeutics by 25.7% in the 3rd quarter. Vanguard Group Inc. now owns 947,876 shares of the biotechnology company’s stock valued at $13,081,000 after buying an additional 193,707 shares during the period. 66.11% of the stock is owned by hedge funds and other institutional investors.

Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.

Further Reading: What is a balanced fund?

Receive News & Ratings for Aldeyra Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Insolar  Trading Up 12.9% Over Last Week
Insolar Trading Up 12.9% Over Last Week
Insider Selling: Cray Inc.  VP Sells 52,409 Shares of Stock
Insider Selling: Cray Inc. VP Sells 52,409 Shares of Stock
Autohome   Shares Down 6.5%
Autohome Shares Down 6.5%
Invesco Multi-Factor Core Fixed Income ETF  Increases Dividend to $0.07 Per Share
Invesco Multi-Factor Core Fixed Income ETF Increases Dividend to $0.07 Per Share
XRP  Price Up 17% Over Last 7 Days
XRP Price Up 17% Over Last 7 Days
Analysts Expect Shutterstock Inc  Will Announce Quarterly Sales of $170.73 Million
Analysts Expect Shutterstock Inc Will Announce Quarterly Sales of $170.73 Million


© 2006-2019 Ticker Report